Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $65.9 million.

  • Cumberland Pharmaceuticals' Liabilities and Shareholders Equity fell 1413.59% to $65.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.3 million, marking a year-over-year decrease of 1231.42%. This contributed to the annual value of $75.6 million for FY2024, which is 757.27% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $65.9 million for Q3 2025, which was down 1413.59% from $67.9 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity peaked at $96.7 million during Q1 2022, and registered a low of $65.9 million during Q3 2025.
  • For the 5-year period, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity averaged around $83.8 million, with its median value being $87.6 million (2021).
  • In the last 5 years, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 1002.29% in 2022 and then crashed by 1419.91% in 2025.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Liabilities and Shareholders Equity stood at $84.5 million in 2021, then rose by 10.02% to $92.9 million in 2022, then decreased by 12.0% to $81.8 million in 2023, then decreased by 7.57% to $75.6 million in 2024, then fell by 12.81% to $65.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $65.9 million in Q3 2025, compared to $67.9 million in Q2 2025 and $69.9 million in Q1 2025.